Clinical trial · no report yet · Phase 3
ATALANTE
ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab
- NCT02891824 ↗
- Completed
- ARCAGY/ GINECO GROUP
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 5 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Ovarian Cancer
- Interventions
- atezolizumab + avastin + platinum-based chemotherapy; placebo + avastin + platinum-based chemotherapy
- Arms
- Arm A: Placebo + Avastin + platinum-based chemotherapy · Placebo comparator
- Arm B: Atezolizumab + Avastin+ platinum-based chemotherapy · Experimental
- Enrollment
- 614
- Primary outcomes
- Efficacy: Progression free survival, where the date of progression is based on investigator assessment using the RECIST version 1.1
- Sponsor
- ARCAGY/ GINECO GROUP with Hoffmann-La Roche
- Start
- Sep 22, 2016
- Primary completion
- Oct 15, 2021
- Results posted
- No
- Registry record
- NCT02891824 · updated Feb 11, 2025
Publications
linked from the registry- Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, Denys H, Rosengarten O, Rodrigues M, de Gregorio N, Martinez Garcia J, Petru E, Kocian R, Vergote I, Pautier P, Schmalfeldt B, Gaba L, Polterauer S, Mouret Reynier MA, Sehouli J, Churruca C, Selle F, Joly F, D'Hondt V, Bultot-Boissier E, Lebreton C, Lotz JP, Largillier R, Heudel PE, Heitz F; ATALANTE/ENGOT-ov29 Investigators. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial. J Clin Oncol. 2023 Oct 20;41(30):4768-4778. doi: 10.1200/JCO.23.00529. Epub 2023 Aug 29. PubMed 37643382